Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...

WeightWatchers announced the departure of CEO Sima Sistani, effective immediately, and board member Tara Comonte, former ...

Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Two naturally occurring molecules could be the key to sustained weight management, offering an organic alternative to ...

Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

Should you, would you, take Ozempic? It's a question I'm asked by friends and it's a hot topic among my scientist colleagues, ...

U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

Per Dr. Wheeler, some signs that metformin may not be working are persistently high blood glucose levels and no improvement ...